GW4064 Alters Gut Microbiota Composition and Counteracts Autism-Associated Behaviors in BTBR T+tf/J Mice.

Scientists tested a drug called GW4064 on mice with autism-like behaviors. The drug improved the mice's social skills and fixed problems with their gut bacteria. Mice with autism-like traits had too many of certain bacteria types, and the drug helped balance this out. This research suggests that targeting gut health might help with autism symptoms, though this was only tested in mice.

This preclinical study investigated whether GW4064, a farnesoid X receptor (FXR) agonist, could improve autism-like behaviors in BTBR mice, an established animal model for autism spectrum disorder. The research focused on the connection between gut microbiota and autism symptoms. Results showed that GW4064 administration successfully improved social behaviors in BTBR mice, including sociability and social reciprocal interactions, while having no effect on typical C57BL/6J mice. The treatment also restored gut microbiota balance by increasing microbial abundance and normalizing the elevated Firmicutes to Bacteroidetes ratio commonly seen in autism models.

These findings suggest a potential therapeutic pathway linking gut microbiota modulation to autism symptom improvement.

While promising for understanding gut-brain connections in autism, this preclinical research requires human studies before clinical application. The findings support investigating gut microbiota as a therapeutic target and suggest FXR agonists warrant further research as potential autism interventions.

This is preclinical research using an animal model, which may not translate directly to humans. Sample size is not reported, limiting assessment of statistical power. The study does not provide long-term follow-up data or mechanistic details about how FXR modulation affects gut-brain communication.

Autism spectrum disorder (ASD) is considered a heterogeneous neurodevelopmental disorder characterized by significant social, communication, and behavioral impairments. The gut microbiota is increasingly considered a promising therapeutic target in ASD. Farnesoid X receptor (FXR) has recently been shown to modulate the gut microbiota. We hypothesized that FXR agonist GW4064 could ameliorate behavioral deficits in an animal model for autism: BTBR TItpr3/J (BTBR) mouse.

As expected, administration of GW4064 rescued the sociability of BTBR mice in the three-chamber sociability test and male-female social reciprocal interaction test, while no effects were observed in C57BL/6J mice. We also found that GW4064 administration increased fecal microbial abundance and counteracted the common ASD phenotype of a high Firmicutes to Bacteroidetes ratio in BTBR mice. In addition, GW4064 administration reversed elevatedand decreasedcontent in the fecal matter of BTBR animals. Our findings show that GW4064 administration alleviates social deficits in BTBR mice and modulates selective aspects of the composition of the gut microbiota, suggesting that GW4064 supplementation might prove a potential strategy for improving ASD symptoms.